HELIOS Kliniken Schwerin GmbH

The Frauenklinik at HELIOS Kliniken Schwerin is conducting studies on colon cancer and advanced gastric adenocarcinoma, aiming to assess new targeted agents and pre‑operative systemic therapies to improve surgical outcomes and survival.

• Colon cancer staging and treatment response
• FGFR2b‑positive stomach and gastro‑esophageal junction adenocarcinoma
• Pre‑operative chemotherapy versus surgery‑first approaches
• Evaluation of novel targeted inhibitors in metastatic disease

Across the site, 24 clinical trials involve 16 investigators, reflecting a strong focus on gastrointestinal oncology.

Research at the clinic includes trials for thyroid eye disease, testing biologic agents that aim to reduce proptosis and improve visual function in affected patients.

• Batoclimab therapy for active thyroid eye disease
• Assessment of proptosis responder rates
• Safety monitoring of subcutaneous immunomodulators
• Patient‑reported outcome measures for eye comfort

The eye‑disease program contributes to the overall portfolio of 24 trials at the Schwerin site.

The department is active in trials addressing acute lymphoblastic leukemia and lymphoblastic lymphoma, evaluating intensive chemotherapy backbones, proteasome inhibition, and novel immunotherapies to boost disease‑free survival.

• High‑risk pediatric Ph+ ALL with imatinib combinations
• Bortezomib addition during consolidation in relapsed ALL
• Blinatumomab post‑consolidation immunotherapy
• Comparative studies of carboplatin versus cisplatin in germ‑cell tumours

These hematologic studies are part of the site’s broader clinical research effort.

Trials focusing on immune checkpoint inhibition explore combinations with chemotherapy in melanoma and triple‑negative breast cancer, seeking to improve progression‑free survival and response rates.

• Atezolizumab plus chemotherapy in triple‑negative breast cancer
• Fianlimab and cemiplimab versus pembrolizumab in advanced melanoma
• Evaluation of PD‑1/PD‑L1 blockade in high‑risk skin cancers
• Biomarker‑driven patient selection for immunotherapy

Immuno‑oncology research complements the site’s extensive oncology portfolio.

The clinic conducts studies on metastatic castration‑resistant prostate cancer and other urologic malignancies, comparing new hormonal agents and combination regimens to enhance overall survival.

• MK‑5684 versus standard androgen‑axis therapies
• Belzutifan plus zanzalintinib compared with cabozantinib in renal cell carcinoma
• Saruparib added to radiotherapy and ADT in high‑risk prostate cancer with BRCA mutation
• Evaluation of novel anti‑androgen combinations

These urogenital cancer trials are integrated within the site’s 24‑trial program.

A broad spectrum of solid‑tumor investigations, including breast cancer, melanoma, renal cell carcinoma, and gastrointestinal cancers, aims to refine treatment sequencing and assess emerging targeted therapies.

• Early‑stage PIK3CA‑mutated breast cancer with inavolisib
• Advanced melanoma with BRAF V600 mutation treated with encorafenib + binimetinib
• FGFR2b‑positive gastric cancer and bemarituzumab combinations
• Renal cell carcinoma trials with belzutifan combinations

The diverse neoplasm portfolio reflects the site’s commitment to multidisciplinary cancer research.

Clinical programs target pediatric and adult brain tumors such as medulloblastoma, ependymoma, and glioma, testing intensified radiotherapy schedules and targeted agents to raise event‑free survival.

• Hyperfractionated‑accelerated radiotherapy for high‑risk medulloblastoma
• Post‑operative chemotherapy strategies for ependymoma
• Valproate addition to chemotherapy in radiation‑ineligible children
• Molecularly guided maintenance therapy for medulloblastoma subtypes

These neuro‑oncology trials contribute to the overall research activity at HELIOS Kliniken Schwerin.

Studies in this area address melanoma and chronic wound healing, evaluating immunotherapy combinations and topical agents to improve disease control and tissue repair.

• Encorafenib + binimetinib for BRAFV600‑mutated melanoma
• Batoclimab for active thyroid eye disease with skin involvement
• Topical allo‑APZ2‑CVU for chronic venous ulcer closure

The skin‑focused research aligns with the site’s comprehensive clinical trial network.